NCT06531473 Laser Outcomes Associated With (Holmium Laser Enucleation of the Prostate) HoLEP Procedures
| NCT ID | NCT06531473 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northwestern University |
| Condition | Urologic Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-03-04 |
| Primary Completion | 2026-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2024-03-04 with a primary completion date of 2026-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary aim is to assess the impact of laser setting frequency and wattage during holmium laser enucleation of the prostate. There is currently no gold-standard laser settings for HoLEP procedures. In the investigator's current high-volume practice, the following settings for enucleation are: 2j 50hz. These settings are conventional settings, but there is no literature to prove optimal laser settings. The investigators hypothesizes that utilization of higher laser settings may be associated with a clinically significant (defined as \> 10%) decrease in procedural time without any detrimental postoperative outcomes, and a utilization of lower laser settings may be associated with a clinically significant (defined as \>10%) reduction in postoperative irritative voiding symptoms without any detrimental postoperative outcomes.
Eligibility Criteria
Inclusion Criteria: * Males 18-89 who are undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms, that are typically caused by enlarged prostates Exclusion Criteria: * Prostates measurements over 200g * Patients who lack decisional capacity * Patients who are non-english speakers
Contact & Investigator
Amy Krambeck, MD
PRINCIPAL INVESTIGATOR
Northwestern University
Frequently Asked Questions
Who can join the NCT06531473 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 89 Years, studying Urologic Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06531473 currently recruiting?
Yes, NCT06531473 is actively recruiting participants. Contact the research team at allaa.fadlalla@northwestern.edu for enrollment information.
Where is the NCT06531473 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06531473 clinical trial?
NCT06531473 is sponsored by Northwestern University. The principal investigator is Amy Krambeck, MD at Northwestern University. The trial plans to enroll 300 participants.